含紫杉醇的放化疗用于老年局部复发性肌层浸润性膀胱癌患者
Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients.
作者信息
Käsmann Lukas, Manig Lisa, Janssen Stefan, Rades Dirk
机构信息
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
出版信息
In Vivo. 2017 Mar-Apr;31(2):239-241. doi: 10.21873/invivo.11051.
BACKGROUND/AIM: To evaluate outcomes and toxicities of chemoradiation with a less intensive paclitaxel regimen for locally recurrent bladder cancer.
PATIENTS AND METHODS
Three elderly patients received simultaneous chemoradiation for recurrent muscle-invasive bladder cancer. Chemotherapy included two courses (three times 25 mg/m over 1.5 weeks) of paclitaxel. Radiotherapy doses were 59.4 Gy to the bladder and 50.4 Gy to regional lymph nodes. Survival, local control and toxicities were retrospectively evaluated.
RESULTS
One patient died after 71 months, two were alive after 69 and 98 months, respectively. No local recurrence was not observed. Five-year survival and local control rates were 100%. Two patients experienced grade 1 acute dysuria, one patient grade 1 diarrhea. Late toxicities were also mild; two patients had grade 1 dysuria.
CONCLUSION
Chemoradiation with a less intensive paclitaxel regimen resulted in excellent 5-year results and was very well tolerated. It may be a reasonable option for elderly patients who cannot tolerate more intensive approaches.
背景/目的：评估采用强度较低的紫杉醇方案进行同步放化疗治疗局部复发性膀胱癌的疗效和毒性。
患者与方法
三名老年患者接受了针对复发性肌层浸润性膀胱癌的同步放化疗。化疗包括两个疗程（在1.5周内三次给予25mg/m²的紫杉醇）。放疗剂量为膀胱59.4Gy，区域淋巴结50.4Gy。对生存情况、局部控制情况和毒性进行回顾性评估。
结果
一名患者在71个月后死亡，两名患者分别在69个月和98个月后仍存活。未观察到局部复发情况。五年生存率和局部控制率均为100%。两名患者出现1级急性排尿困难，一名患者出现1级腹泻。晚期毒性也较轻；两名患者有1级排尿困难。
结论
采用强度较低的紫杉醇方案进行同步放化疗取得了优异的五年疗效，且耐受性良好。对于无法耐受更强化治疗方案的老年患者而言，这可能是一个合理的选择。
Zotero 插件